← Back to Search

personalized ultrafractionated stereotactic ablative radiotherapy for Bladder Cancer (CIRTiN-BC Trial)

N/A

Waitlist Available

Led By Solomon L Woldu, MD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

CIRTiN-BC Trial Summary

This trial is testing a new type of radiation therapy to see if it's feasible and effective for patients with bladder cancer who are unable to receive or respond to chemotherapy.

Eligible Conditions

Bladder Cancer

CIRTiN-BC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Protocol Completion

Secondary outcome measures

Progression-free Survival

Other outcome measures

Major Complication Rate

Pathologic Complete Nodal Response

Pathologic Complete Response

+4 more

CIRTiN-BC Trial Design

1Treatment groups

Experimental Treatment

Group I: PULSARExperimental Treatment1 Intervention

Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,050 Previous Clinical Trials

1,054,358 Total Patients Enrolled

Solomon L Woldu, MDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any potential dangers associated with personalized ultrafractionated stereotactic ablative radiotherapy?

"While there is some evidence backing the safety of personalized ultrafractionated stereotactic ablative radiotherapy, it remains unproven in terms of efficacy. Consequently, our team has given it a 2."

Answered by AI

Are there any current openings for new participants in this trial?

"That is correct, the trial is still actively recruiting patients according to the most recent update on clinicaltrials.gov from February 24th, 2022. This study was first posted on September 6th, 2021 and is looking for 27 participants total at 1 site."

Answered by AI

How many people can take part in this experiment?

"Per the information available on clinicaltrials.gov, this trial is still recruiting patients. The listing for the study was first created on September 6th, 2021 and last updated February 24th, 2022. So far, only 27 of the needed participants have been recruited from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

Solomon Woldu 2021. "Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04779489.